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Abstract
Background: Rejection of transplanted tumors by the immune system is a rare event in syngeneic
hosts, and is considered to be dependent on the local interaction of defensive immune reactions
and tumor tolerance mechanisms. Here, we have enlisted the aid of a unique set of embryo-
aggregated lineage chimeric mice derived from C57/BL6 and FVB donors to study the interplay
between local and systemic tumor immunity and tolerance in rejection of mouse B16 melanoma
cells, syngeneic to the C57/BL6 donor strain.
Methods: Two variants of embryo-aggregated chimeric mice with either variable or no
contribution of C57-derived cells to their skin were generated by the fusion of different ratios of
morula stage blastomers. Chimeric mice were analyzed for s.c. growth of B16 tumors in
comparison to their respective donor strains as well as normal F1 hybrids, and the relative
frequencies of cellular components of the immune system by FACS analysis of peripheral blood or
lymph node cells.
Results: B16 tumors grew significantly faster in mice with full chimerism in their skin as compared
to syngeneic C57 or semi-syngeneic C57 × FVB F1 hosts. In contrast, s.c. tumor growth was either
absent or significantly reduced in chimeric mice lacking C57-derived cells in their skin, but tolerant
to C57 tissue in other organs. Comparison of the relative frequencies of various immune cells in
the periphery via FACS-analysis did not reveal any significant differences between the two types of
chimeric mice with respect to their donor strains.
Conclusion: Our data suggest a complex interplay between mechanisms of local peripheral
tolerance and innate antitumor mechanisms possibly involving NK cell allorecognition as a basis for
the differential growth or rejection of B16 tumors in these unique chimeric mice, which we suggest
to constitute a valuable new model system for the study of immune-mediated tumor rejection.
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While recent advances in tumor immunology have led to
the establishment of methods of generating significant
clinical anti-tumor immune responses, outright tumor
rejection has proved elusive in most cases. Therefore, an
understanding of the distinct difference between an anti-
tumor immune response and outright tumor rejection
remains an important goal within the field of tumor
immunology. B16 melanoma tumors in the C57/6J
mouse strain represent one of the most commonly stud-
ied murine models for tumor immunotherapy. It is well
known that the B16 cell line will grow and quickly estab-
lish tumors when injected s.c. or i.v. in syngeneic C57BL/
6J mice. Discrete tumor rejection in this system would
thus serve as a good model for effective immunotherapy.
Tumor rejection in syngeneic mice is believed to be the con-
sequence of recognition of discrete tumor antigens by the
host's immune system, predominantly via recognition of
mutated or over-expressed "self" peptides displayed in the
context of MHC-I molecules by cytotoxic (CD8+) T lym-
phocytes [1]. On the other hand, as shown in a series of ele-
gant studies by North and colleagues in the 1980's [2],
establishment of a tumor-specific cytotoxic T cell response
per se usually is not sufficient to eradicate transplanted
tumors or restrict their growth. This state of "concomitant"
tumor immunity has been attributed to tumor tolerance via
active immune suppression mechanisms exerted by tumor-
specific suppressor T cells [3,4]. This concept has been
revived in recent years by the discovery of so-called regula-
tory T cells (Treg) as crucial elements of immunologic self
tolerance [5] but also of induced tolerance to growing
tumors [6]. Thus paradoxically, tumors may grow and
eventually kill their hosts despite systemic antitumor
immunity, due to localized tumor-antigen-specific suppres-
sion of the co-existing protective immune response.
In accordance with the principles of transplantation
immunology, transplanted tumors usually grow just as
well in semi-syngeneic F1 offspring of their syngeneic
hosts as in the latter, whereas the same tumor is rapidly
rejected by the allogeneic counterpart as a consequence of
allorecognition of the tumor cell's MHC/peptide com-
plexes [7], representing the two extremes of tumor toler-
ance vs tumor rejection. Apart from semi-syngeneic mice,
embryo-aggregated chimeric mice (not to be confused
with "hematopoietic chimeras" generated by bone mar-
row transplantation) will also harbor the same genetic
background derived from both donor strains, albeit in still
distinct cells dispersed throughout the body, and thus
may serve as an attractive alternative model for tumor
immunity. Aggregation of the blastomers from morula
stage embryos of two disparate mouse lines results in the
formation of a chimeric morula that develops into a
mouse that contains cells from the two distinct parental
backgrounds [8]. In this manner it is possible to generate
mice that contain a mixture of cells from two allogeneic
mouse lines. The immune system of these chimeric mice
therefore should and in fact has been shown to be tolerant
to all cell types present within the chimeric mouse [9],
which is consistent with the normal health status of these
mice.
While such embryo-aggregated chimeric mice have been
produced by and known to embryologists for several dec-
ades [10,11], a unique class of these chimeric mice have
been generated for this study that have not been previ-
ously reported. In addition to full chimeric mice, chimeric
mice devoid of one of the two allogeneic parental back-
grounds within their skin have been generated to study
the role of the local genetic environment on tumor toler-
ance vs tumor rejection. These unique chimeric mice have
contributions from the C57 strain in earlier developing
tissues that derive from the mesendoderm, precursor of
the endoderm and mesoderm, (tissues derived from the
mesoderm include the heart and blood as well as others
while other internal organs such as lung, liver, digestive
system and thymus [12] derive from the endoderm) in
spite of the decreased number of C57 blastomers present
in the developing chimeric embryo but lack contributions
from this strain in ectoderm derived skin. While some
studies on the susceptibility of chimeric mice to spontane-
ous tumor development have been performed (reviewed
in [13]), to our knowledge, this report is the first attempt
to use such mice as a system to study tumor immunology
with a defined transplantable tumor model. By compar-
ing s.c. B16 tumor growth in syngeneic C57BL/6J mice,
allogeneic FVB/NJ mice, semi-syngeneic C57 × FVB F1
mice, fully chimeric C57/FVB mice and C57/FVB chimeric
mice devoid of C57 skin, a complex interplay of local
immune tolerance and defense mechanisms in distinct
tumor rejection is suggested.
Methods
Mice
FVB/NJ and C57/BL6J mice were from Jackson Laborato-
ries (Bar Harbor, ME) and CD1 mice were from Charles
River Laboratories (Willmington, MA). All mice were
housed in the Oncology Research Institute's animal facil-
ity and were pathogen free. Experiments performed were
in compliance with the guiding principles of the Guide for
the Care and Use of Laboratory Animals (available at http://
www.nap.edu/books/0309053773/html) and approved
before use by the Institutional Animal Care and Use Com-
mittee of the Greenville Hospital System University Med-
ical Center.
Collection of embryos
Donor FVB/NJ (FVB) and C57BL/6J (C57) female mice
were superovulated with i.p. injections of 5 IU of Pregnant
Mare Serum Gonadotropin (Calbiochem; Gibbstown, NJ),
followed 48 h later by i.p. injections of 5 IU of human cho-Page 2 of 12
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MO). The donor mice were mated to FVB and C57 stud
males. 46 h after mating, donor females showing vaginal
plugs were sacrificed, and 2-cell embryos were flushed from
the oviducts using a 30 G 1/2 inch needle attached to a 3 ml
syringe filled with M2 medium. The embryos were washed
several times in 75 μl micro drops of M16 medium and cul-
tured 24 h to 8-cell in 50 μl micro drops of M16. All micro
drops used for embryo culture and manipulation were cov-
ered with mineral oil (Sigma Chemical Company; St. Louis,
MO) in 60 mm petri dishes. Dishes with M16 medium
were kept at 37°C in a 5% CO2/air mixture, and dishes with
M2 medium were kept at 37°C in air. M2 and M16 media
were made in-house.
Preparation of embryos
The zona pellucidas were removed from the FVB and C57
8-cell embryos by placing them into 100 μl micro drops
of a 0.5% protease (Sigma Chemical Company; St. Louis,
MO) in M2 solution for 10 min at 37°C. The zona free
embryos were washed by passage through several 75 μl
micro drops of M16 and placed in M16 holding drops.
Individual C57 blastomeres were generated from C57
embryos by placing them into 100 μl micro drops of Mg++
and Ca++ free Dulbecco's PBS (Gibco; Carlsbad, CA) plus
0.6% BSA (Sigma Chemical Company; St. Louis, MO) for
15 to 20 min at room temperature. Separation of the blas-
tomeres was aided by gentle pipetting with a flame pol-
ished embryo transfer pipette.
Aggregation of embryos
Aggregation plates were prepared by placing multiple 25
μl M16 drops covered with mineral oil in 60 mm petri
dishes and concave depression wells were made in the
center of each M16 drop by firmly pressing an aggregation
needle (BLS; Hungary) into the plastic. The plates were
kept at 37°C in 5% CO2 in air. FVB 8-cell embryos were
paired with 8-cell C57 embryos in the depression wells.
FVB 8-cell embryos were also paired in various combina-
tions with individual C57 blastomeres at 1:8, 2:8, 3:8, and
4:8 (C57: FVB) ratios in the depression wells to attempt to
generate chimeras with some wholly FVB tissues. The
aggregated embryos were cultured at 37°C in 5% CO2 in
air for 24 h until they developed into early blastocysts.
Pseudopregnant CD1 (Charles River Laboratories, Wilm-
ington, MA) female recipient mice at 0.5 and 2.5 days post
conception (dpc) were anesthetized with a 1.4% avertin
solution in PBS (0.1 ml/5 g of body weight). 14 to 20
aggregated blastocysts were transferred into the oviducts
of each 0.5 dpc recipient mouse, and the uterine horns of
each 2.5 dpc mouse.
Generation of chimeric mice
255 aggregates were made and transferred into 15 CD1
recipient females. 66 pups were born or taken by cesarean
section. 52 pups survived. Nine mice had varying ratios of
black and white coat color, and ten were later identified as
white coat chimeras by flow cytometric analysis of their
blood lymphocytes.
Tumor cell culture
B16-F0 murine melanoma cells were obtained from ATCC
(Manassas, VA) and cultured in DMEM (Fisher; Pitts-
burgh, PA) modified with 10% FBS (Fisher). Cells were
cultured at 37°C in the presence of 5% CO2. Cells were
harvested by trypsinization and washed in PBS prior to
use for tumor inoculation.
Mouse tumor challenge
Five C57BL/6J, five FVB/NJ, five C57BL/6J × FVB/NJ F1
hybrids (C57 × FVB), six C57/FVB chimeras with black
and white segmented coat color and five C57/FVB chime-
ras with pure white coat color were injected intradermally
with 1 × 106 B16-F0 cells. All mice were inoculated with
B16-F0 tumor cells between 40 and 50 days of age. At day
18 post tumor cell inoculation mice with tumors esti-
mated to weigh more than 1 g were sacrificed by CO2
asphyxiation and mice with smaller tumors were anesthe-
tized with a 1.4% avertin solution in PBS (0.1 ml/5 g body
weight) and the tumors excised and weighed. Following
removal of the smaller tumors from anesthetized mice the
small incision remaining after tumor excision was closed
using a sterile wound clip.
Determination of H-2Kb (C57) and H-2Kq (FVB) leukocyte 
percentages in mice
In order to determine the haplotype (H-2Kb/H-2Kq) per-
centage ratio of white blood cells in control and chimera
mice, white blood cells were isolated from mouse whole
blood, stained with the cognate fluorescent antibodies
and analyzed by flow cytometery. Blood was collected
from the tails of mice by use of a heparin coated blood
collection tube, Fisher (Pittsburgh, PA) and 0.5 M EDTA
added to prevent coagulation. Approximately 100 μl of
blood was collected from each mouse, 2 ml of 1 × FACS-
lyse buffer (BD Biosciences; Hayward, CA) added to lyse
the red blood cells and the suspension was incubated at
RT for approximately 10 min. Samples were then centri-
fuged at 300 × g for 5 min at room temperature and
washed twice with PBS.
Approximately 1 million white blood cells were resus-
pended in staining buffer (1% FBS, 0.1% sodium azide,
PBS) for each reaction and then 1 μg of the appropriate
antibody was added. Both H-2Kb (clone AF6-88.5) and H-
2Kq (clone KH114) antibodies were FITC conjugated and
obtained from BD Biosciences (San Jose, CA). Cells were
incubated with antibody for 30 min on ice in the dark and
then washed twice with staining buffer. Cells were resus-
pended in 250 μl of staining buffer and then analyzed.Page 3 of 12
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gies (Hayward, CA) was used for flow cytometric analysis.
Various leukocyte populations were gated and 10,000
events were analyzed using the GUAVA Express Plus pro-
gram. Data was then analyzed by use of CytoSoft 3.6.1
software.
Analysis of the percentage CD4+, CD8+, and CD45/B220+ 
lymphocytes in control and chimeric mouse blood
In order to analyze the percentage of CD4+, CD8+, and
CD45/B220+ lymphocytes in the blood of control and chi-
meric mice, 50 μl of whole blood was collected via a
heparin coated bleeding tube and added to 1 ml of wash
buffer (1% FBS, 0.1% sodium azide, PBS). Cells were then
pelleted by centrifuging at 500 × g for 5 min. All superna-
tant was removed from the cell pellet except for approxi-
mately 200 μl. 10 μg of rat IgG (BD biosciences; San Jose,
CA) was then added and each sample incubated on ice for
15 min. Rat IgG was added to the samples to block non-
specific antibody binding to the cells. 0.5 μg each of anti
CD4, CD8, and CD45/B220 antibodies were added to
each sample and the mixture then incubated for 30 min
on ice in the dark. All antibodies were obtained from BD
Biosciences and anti-CD4 was PE-conjugated, anti-CD8
was FITC-conjugated, and anti-CD45/B220 was PE-Cy5-
conjugated. Following antibody incubation, cells were
washed once with wash buffer and then 1 ml of ACK lys-
ing buffer (Cambrex; East Rutherford, NJ) was added to
lyse the red blood cells. Samples were incubated for 5 min
in ACK lysing buffer at RT. Samples were then washed
once with wash buffer and resuspended in 300 μl of wash
buffer. Cells were analyzed using the BD FACS Calibur
and data analyzed using the Cell Quest program.
Analysis of the percentage CD4+CD25+Foxp3+ Treg cells in 
control and chimeric mouse lymph nodes
Lymph nodes were obtained from C57, FVB, C57FVB F1
hybrids, C57/FVB chimeras with black and white seg-
mented coat color and C57/FVB chimeras with pure white
coat color and single cell suspensions in FACS buffer
(phosphate-buffered saline containing 0.1% sodium
azide and 0.1% bovine serum albumin) were obtained by
pressing tissues through a 40 μm Nylon Cell Strainer (BD
Biosciences Discovery Labware, Bedford, MA) with a
syringe plunger (BD Biosciences Discovery Labware, Ded-
ford, MA). After centrifugation at 1500 rpm for 5 min, the
cell pellet was resuspended in ACK lysing buffer (Lonza,
Walkersville, MD) for 5 min to lyse red blood cells. The
cells were then washed with FACS buffer twice and
counted. 1 × 106 cells in 50 μl FACS buffer were used for
each staining. After the cells were incubated with 10 μg/
sample rat IgG (Zymed Laboratories, South San Francisco,
CA) on ice for 15 min, 1 μg/sample of FITC-labeled rat
anti-mouse CD4 and PE labeled rat anti-mouse CD25
(BD Biosciences Pharmingen, San Jose, CA) were added
respectively and incubated on ice for another 30 min. The
cells were further washed with FACS buffer. After the cells
had been stained with CD4-FITC and CD25-PE and
washed they were fixed and permeabilized using a Fixa-
tion/Permeabilization kit (BD Bioscience, San Jose, CA)
and then incubated with PE-Cy5 labeled rat anti-mouse
Foxp3 antibody (eBioscience, San Diego, CA) for 30 min,
washed with the Perm/Washing buffer provided with the
kit, resuspended in FACS buffer and analyzed on the BD
FACSCalibur. The FACS data was analyzed using the Cell
Quest program.
Statistical analysis
Statistical relevance of experimental data was assessed by
the Student's t-test.
Results
Growth of B16 tumor cells in C57/FVB chimeric mice
Embryo-aggregated chimeric mice with different levels of
chimerism between C57 and FVB tissues were generated
by varying the ratio of C57 blastomers with respect to FVB
8 cell embryos. Variations in chimerism were especially
notable in the contribution of C57 to the skin of chimeric
mice, ranging from black and white segmented over
minor patches of black to pure white (FVB) coat colour
(Fig. 1). Yet, even the latter showed an, albeit reduced,
level of chimerism with respect to their blood cells (Table
1). All types of chimeras were healthy and did not show
any evidence of an abnormal immune status in terms of
enhanced sensitivity to spontaneous infections or autoim-
mune disease. Nevertheless, individual chimeric mice
showed dramatic differences in terms of growth or rejec-
tion of s.c. injected B16 melanoma cells of C57 origin,
which was clearly correlated with the level of skin chimer-
ism (Table 1). Whereas B16 tumors grew rapidly in mice
with substantial coat chimerism (termed fully chimeric
mice herein), tumor growth in mice with overly white,
FVB-derived skin (termed partial chimeras herein) was
either marginal, yielding minute, largely necrotic tumors,
or not observed at all. Fig. 2 gives a quantitative compari-
son of B16 tumor growth in these two types of chimeric
mice with growth of the same tumor in either allogeneic
FVB mice, the syngeneic host C57 or C57 × FVB F1 as the
control most closely matching the genetic setup of the chi-
meras. Evidently and as expected, FVB mice fully rejected
the tumor transplant, whereas there was no difference in
tumor growth between the syngeneic C57 host and the
semi-syngeneic C57 × FVB F1. Quite remarkably however,
as compared to these controls, tumor growth was either
significantly enhanced or suppressed in the two types of
chimeric mice. Thus, the level of skin chimerism with
respect to C57 derived tissue exerted a marked influence
on the growth or rejection of the C57-derived tumor in
otherwise chimeric mice. Reduced tumor size in partial
chimeras was not due to delayed rejection of tumors ini-Page 4 of 12
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tumor rejection or growth suppression. Interestingly how-
ever, two of the partially chimeric mice (mice #8 and #10)
that rejected the primary s.c. tumor inoculum developed a
quite massive tumor in the peritoneal cavity 6 – 8 weeks
later, demonstrating that these mice are not generally
rejecting these B16 tumors, but effectively do so in their
skin.
Immune system of chimeric mice
These quite unexpected differences in tumor growth or
rejection prompted us to analyze the relative frequencies of
various cells of the adaptive immune system in these chi-
meric mice in comparison to the respective "parental" con-
trols or the F1 offspring. However, apart from a marked
expansion of the T cell over the B cell compartment in FVB
vs C57 donor strains, no significant differences between
these groups of mice in terms of total blood T and B lym-
phocytes, and notably also CD4+CD25+Foxp3+ Treg cells in
lymph nodes were observed (Fig. 3). Haplotype frequen-
cies of individual lymphocyte subsets were also tested for
some chimeric mice, but did not reveal significant differ-
ences from the respective frequencies of total lymphocytes
(data not shown), suggesting that there is no specific hap-
lotype bias for individual lymphocyte subsets in chimeric
mice. The same is also true for the numbers and haplotype
frequencies of predominant cells of the innate immune sys-
tem (neutrophils and blood monocytes (data not shown),
demonstrating that there is no gross alteration in the basic
constituents of the immune system in these chimeric mice,
which is in line with their normal overall health status.
Discussion
Because the observations and results described herein
derive from the first study of the development of a defined
transplantable tumor in embryo-aggregated chimeric
mice, more questions than answers may have emerged.
Nonetheless, two predominant observations are that B16
tumors grow significantly faster in full chimeric mice than
in their syngeneic hosts or C57 × FVB F1 offspring and
that these same B16 tumors are either fully or partly
rejected within the skin of chimeric mice with a non-chi-
meric skin allogeneic to the tumor implant, although
these unique chimeras are tolerant toward C57-derived
tissue in other organs. Clearly, established and accepted
precepts of present day immunology would not predict
either the enhanced growth of B16 tumors in fully chi-
meric C57/FVB mice or the rejection of these same tumors
in the same partially chimeric mice since both of these
hosts should be tolerant for the MHC class b haplotype of
these tumor cells, as suggested by early transplantation
studies with chimeric mice, termed "allophenic" by these
authors [9]. While at first glance the results reported in
their paper would also imply a selective rejection of "mis-
matched" donor normal skin transplants by single color-
coated "allophenic" recipient mice, no evidence for actual
chimerism of these mice was presented. Since it is well
established that in vitro aggregation of blastomers from
two different donors quite often does not result in the
generation of detectable chimerism [11] (A. K. Tarkowski,
personal communication), these "allophenic" mice,
unlike the ones reported here with proven chimerism,
rather have to be considered as essentially non-chimeric.
In fact, a later study of the same group [14] failed to dem-
onstrate chimerism in various tissues of the vast majority
of such single color-coated "allophenic" mice, suggesting
the observed rejection of unmatched donor skin to be due
to classical allograft rejection, and thus to be mechanisti-
cally unrelated to the findings presented here.
While at the current status of experimental work the fol-
lowing discussion has to remain largely speculative, the
Table 1: Relative chimerism of individual mice versus tumor progression
C57/FVB Mouse Chimera Coat Chimerism Hematopoietic Chimerism H2Kb/H2Kq 
(% Lymphocytes)*
B16-F0 Tumor Weight at Day 18 Post
Injection
#1 C57/FVB 56/44 5478 mga
#2 C57/FVB 52/48 5802 mga
#3 C57/FVB 42/58 4310 mga
#4 C57/FVB 57/43 5021 mga
#5 C57/FVB 51/49 5724 mga
#6 C57/FVB** 36/64 16 mgb
#7 Only FVB 9/91 No Tumor
#8 Only FVB 7/93 No Tumorc
#9 Only FVB 7/93 24 mgb
#10 Only FVB 5/95 14 mgb,c
#11 Only FVB 8/92 31 mgb
*- Haplotype frequencies determined for whole blood lymphocytes
**- The black (C57) coat color contribution was minimal. See Figure 2.
a- Mouse was sacrificed at day 18.
b- Tumor was surgically removed on day 18 and the mouse continued to be monitored. Resected tumors were largely necrotic at time of resection.
c- Died of a large peritoneal tumor 8 weeks following s.c. tumor cell injectionPage 5 of 12
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rent concepts of allorecognition, tolerance and tumor
immunity, in search for possible explanations for the
enhanced growth vs rejection of the B16 tumors in these
two variants of chimeric mice.
The concept of immunological tolerance is based on two
basically independent mechanisms, termed central and
peripheral tolerance, respectively, leading to clonal dele-
tion and/or functional inactivation of autoreactive lym-
phocytes [15]. Since rejection of tissue transplants is
known to be mainly based on alloreactive T cells [16], we
will limit our further discussion on mechanisms operative
in T cell tolerance. Central tolerance to self tissue antigens,
considered to be the predominant mode of tolerance
[17,18], of both CD4+ and CD8+ T cells is acquired in the
thymus by clonal deletion of T cells reactive to self anti-
gens displayed by epithelial cells and/or dendritic cells
(DC) in the thymic medulla during T cell maturation [19].
Whereas clonal deletion of CD4+ T cells seems to be pri-
Images of several mouse chimeras generated by fusion of C57 8-cell and C57 blastomers with FVB 8-cell embryosFigure 1
Images of several mouse chimeras generated by fusion of C57 8-cell and C57 blastomers with FVB 8-cell 
embryos. A) typical C57/6J mouse, B) a typical FVB/NJ mouse, C) mouse # 2, a C57/FVB chimera produced by the fusion of 
FVB and C57 8-cell embryos with black and white segmented coat color, D) mouse #4 another C57/FVB chimera produced by 
the fusion of FVB and C57 8-cell embryos with black and white segmented coat color, E) mouse #6 another C57/FVB chimera 
produced by the fusion of FVB and C57 8-cell embryos with minimal black and predominate white segmented coat color and F) 
Mouse #8 a C57/FVB chimera produced by fusion of 2 C57 blastomers with an FVB 8-cell embryo with pure white coat color.Page 6 of 12
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tures displayed in the thymus by thymic DC's, central
tolerance at the level of CD8+ T cells is established pre-
dominantly via presentation of internal self epitopes on
the MHC-I molecules on thymic epithelial cells, although
thymic DC's may also participate in this reaction [20].
Wide coverage of self structures is ensured by the random
expression of peripheral tissue antigens under the control
of the autoimmune regulator (AIRE) element and other
less well characterized mechanisms [21,22]. Peripheral
tolerance, considered as a polishing mechanism for auto-
reactive clones that have escaped the mechanisms of cen-
tral tolerance or clones directed to tissue specific self
peptides not displayed in the thymus [23], is based on
several independent mechanisms, clonal anergy, activa-
tion-induced cell death (AICD) [23] and the generation of
antigen-specific CD4+ and CD8+ Treg cells [24]. The com-
mon aspect of these mechanisms is antigen recognition in
lack of appropriate costimulatory signals or by specific
tolerogenic/polarizing signals provided by quiescent anti-
gen presenting cells in peripheral tissues [25-27]. Whereas
anergy and AICD may be viewed as a continuation of
clonal deletion of functional T-cells in the periphery with-
out direct impact on the local immunological environ-
ment, Treg cells exert their effect by local suppression of
immune reactions either via deletion or functional inacti-
vation of activated immune cells or via inhibitory
cytokines like TGF-β, IL-10 or IL-35 [28], thus dominantly
affecting immunity locally in response to specific anti-
gens, albeit lacking antigen specificity.
In a chimeric thymus, central tolerance to all types of self
antigens should be established, including the MHC mole-
cules of both "parental" strains just as in normal F1 off-
spring. However, there may be one fundamental
difference between F1 offspring and chimeras in terms of
antigen presentation via MHC-I molecules, which may
necessitate enhanced peripheral tolerance of the CD8+ T
cell compartment. In F1 offspring, due to heterozygosity,
self peptides derived from either one or the other strain
will be more or less randomly presented by MHC-I mole-
cules of both strains, resulting in a larger variation of
potential self structures displayed in the thymus. In chi-
meras, on the other hand, self peptides derived from
Tumor weights in normal and chimeric mice at day 18 following intradermal inoculation with 1 × 106 B16-F0 tumor cellsFigure 2
Tumor weights in normal and chimeric mice at day 18 following intradermal inoculation with 1 × 106 B16-F0 
tumor cells. Each group includes 5 mice. The B/W coat chimera group includes mice # 1–5 from Table 1 and the White coat 
chimera group includes mice # 7–11 from Table 1. Error bars represent standard deviations of samples from individual mice. 
Differences in tumor weight of the B/W coat chimera group and the W coat chimera group with respect to the C57 × FVB F1 
control group are highly significant (p < 0.001 for both sets).Page 7 of 12
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context of the donor-specific MHC-I molecules on thymic
epithelial cells. As a consequence, CD8+ T cell clones reac-
tive to peptides of strain A in the context of MHC-I of
strain B may not be deleted at an equal efficiency as
"matched pairs", resulting in a larger number of surviving
clones with potential autoreactivity, although these clones
should not be able to directly attack normal tissue cells
due to classical MHC restriction [29]. Conversely, as
pointed out above, since tolerance induction for CD4+ T
cells is primarily based on presentation of endocytosed
"external" structures and thus by definition is promiscu-
ous with respect to peptides and MHC-II molecules of
both donors, no differences would be expected at the level
of central tolerance of CD4+ T cells or CD4+ Treg cells,
which is in agreement with our findings.
Further maturation of effector T cells from antigenically
predetermined naïve T cells is dependent on antigen pres-
entation by DC's [30]. With respect to MHC-I restricted
CD8+ T cells, stimulation of naïve T cell clones by tissue
antigens requires so-called "cross presentation" of struc-
tures picked up in the periphery from dead cells on the
MHC-I molecules of DC's [31]. Since in chimeric mice
DC's should pick up material from dead cells irrespective
of their descent, self peptides of strain A should now also
show up on the MHC-I molecule of strain B and vice
versa. But in lack of appropriate "danger signals" and thus
costimulation [32], this should again result in the induc-
tion of peripheral "cross tolerance" [33]. In contrast to
normal F1 offspring however, in chimeric mice, there
should still be plenty of potentially reactive CD8+ clones
available, due to lacking clonal deletion in the thymus.
Consequently, this should also give rise to a larger
number of CD8+ but not CD4+ Treg clones that in turn
should serve to dampen local immune responses, and
thus may explain enhanced tumor growth in the fully chi-
meric skin or the chimeric organs of the partial chimeras.
As this should represent a local phenomenon, driven by
cross presentation of tissue antigens, the extent of this
Percentage of CD4+ T cells, CD8+ T cells, B220+ B cells and CD4+CD25+Foxp3+ Treg cells in normal and chimeric miceFigure 3
Percentage of CD4+ T cells, CD8+ T cells, B220+ B cells and CD4+CD25+Foxp3+ Treg cells in normal and chi-
meric mice. A) Percentage of CD4+ T cells per total blood lymphocytes. Each group includes 3 mice 30–40 days of age. The 
B/W chimera group includes mice # 3–5 from Table 1 and the W chimera group includes mice # 9–11 from Table 1. B) Per-
centage of CD8+ T cells per total blood lymphocytes. Each group includes 3 mice 30 – 40 days of age. The B/W chimera group 
includes mice # 3 – 5 from Table 1 and the W chimera group includes mice # 9 – 11 from Table 1. C) Percentage of B220+ B 
cells per total blood lymphocytes. Each group includes 3 mice 30 – 40 days of age. The B/W chimera group includes mice # 3 – 
5 from Table 1 and the W chimera group includes mice # 9 – 11 from Table 1. D) Percentage of CD4+CD25+Foxp3+ Treg cells 
per total lymph node lymphocytes. Each group includes 4 mice 30 – 40 days of age. The B/W and W chimera groups include 
mice different from those described in Table 1 since it was necessary to sacrifice these mice to recover their lymph nodes.Page 8 of 12
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tissues. Interestingly, this notion may get support from
early studies on immune tolerance mechanisms in
embryo-aggregated chimeric mice [34], demonstrating
low but significant in vitro cytotoxicity of isolated lymph
node cells from chimeric mice against normal donor
fibroblasts which however is specifically suppressed by a
soluble factor in the sera of these mice. Although per-
formed well before the era of modern T cell immunology,
these experiments would argue for some active suppres-
sion mechanism of potentially "autoreactive" cells in
these chimeric mice that have escaped central tolerance
mechanisms and thus would be in accordance with the
concept outlined above.
However, this hypothesis cannot explain the enhanced
tumor rejection observed in the non-chimeric skin of par-
tial chimeras compared to the syngeneic host. If, as classic
immunology would suggest, tumor cells are rejected by
allogeneic hosts as a result of either direct or indirect
allorecognition of the foreign MHC/peptide complexes by
the host's T cell receptors [35,36] then such allorecogni-
tion should not occur within a chimeric mouse co-toler-
ant for the MHC molecules of both its tissue types and
cells of either of these tissue types should not be rejected.
While this is indeed the case with the fully chimeric mice,
rejection or partial rejection is clearly observed in hosts
tolerant of the tumor cell's MHC haplotype in the chi-
meric mice with a non-chimeric skin. Since this rejection
by definition cannot be the result of classical allorecogni-
tion we have to look elsewhere for its origin. The most
obvious explanation would be that these mice lack toler-
ance specifically to some C57 skin antigens to which their
immune system was never exposed and thus mount a nor-
mal immune response to these structures. Current con-
cepts of central tolerance would however predict random
expression of various tissue antigens in the thymus
[21,22]. Thus, even in all-white skin partial chimeras,
skin-specific antigenic peptides of both donor strains
should be expressed in the thymus. As a consequence,
there should be no difference in central tolerance to these
structures between full and partial chimeras. But given the
lower overall percentage of chimerism in the latter, it may
be argued that some C57 skin antigens may have slipped
from central tolerance induction in these mice. However,
three lines of experimental evidence argue against this sce-
nario. First, chimeric mice which do have small patches of
C57-derived skin (mouse #6) and thus must be tolerant to
C57 skin antigens nevertheless rejected the s.c. B16 tumor
implants to the same extent as pure white skin chimeras.
Second, delayed growth of a large secondary tumor in the
peritoneal cavity of two of the latter (mice #8 and #10)
that had rejected the B16 tumor cells within their skin
demonstrates that these mice were not immune to the
tumors in their chimeric tissues, even though the number
of tumor cells that may have escaped to the peritoneal cav-
ity must have been only a small fraction of the cells inoc-
ulated s.c., probably also reflecting the suppressive
environment in chimeric tissues discussed above. In addi-
tion, this further argues against a conventional allore-
sponse as the basis for tumor rejection. Third, rejection of
the tumor cells via induction of a classic adaptive response
would have been expected to result in delayed destruction
of tumors after a phase of normal initial growth, which is
in contrast with our experimental findings. Thus taken
together, although not formally ruled out at the current
status of experimental work, enhanced rejection or growth
restriction of B16 tumors in partial chimeras via a classical
T cell mediated or otherwise adaptive immune response
alone does not seem to constitute a likely scenario, sug-
gesting other immune mechanisms as key players.
In fact, it has long been established, that rejection of
tumors by the immune system also involves innate mech-
anisms, executed mainly by macrophages and NK cells
[37,38]. With respect to macrophage-mediated antitumor
mechanisms, differences between partial chimeras and
the syngeneic host are hardly conceivable, since macro-
phage tumor cell recognition and destruction is not
related to strain specificities and has been shown to work
even across species barriers [39]. NK cells, on the other
hand, recognize their target cells by a lack of inhibitory
self structures, namely MHC-I molecules, recognized by a
family of clonally distributed NK cell inhibitory receptors
[40-42]. Thus, it has been demonstrated, that NK cells are
capable of alloreactivity due to mismatched MHC-I mole-
cules [43,44]. However, this phenomenon is not sufficient
for rejection of normal tissue grafts, but has been shown
to have marked effects on the survival of hematopoietic
grafts [45] and the growth of allogeneic tumors [46-48],
and thus has led to trials for adoptive transfer of alloge-
neic NK cells for the treatment of cancer [49-52]. While
still a lot remains to be learned about selective NK activity
against allogeneic tumors, the current interpretation of
these observations is, that activation of NK cell mediated
cytotoxicity requires a second stimulus in addition to mis-
matched or missing MHC-I, provided by stress-induced
ligands for activating receptors on NK cells such as the
NKG2D-receptor [53,54], which are abundant on many
tumor cell types but are absent on most normal tissue cells
[55,56].
How might this translate to tumor rejection in the chime-
ras? B16 tumor cells should be recognized by FVB NK
cells, which constitute the vast majority of NK cells in the
white skin chimeras, both by their lack of proper match-
ing MHC-I molecules and via recognition of stress mark-
ers, whereas normal tissue cells should lack the latter, and
should thus be spared. In fact, B16 tumor cells are known
targets for NK activity [40], despite some level of MHC-IPage 9 of 12
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tion of the inhibitory receptors are overridden by signals
from as yet unknown ligands for NK activating receptors,
as B16 cells do not express ligands for the NKG2D recep-
tor on NK cells [55]. In addition to NK cell mediated kill-
ing of tumor cells, activated NK cells would also provide
the appropriate cytokine signals for activation of macro-
phage antitumor functions [38], starting a concerted
innate tumor defense reaction. This may actually explain
the enhanced rejection of the B16 tumors in the skin of
partial chimeras as compared to the syngeneic host, where
no activation of NK cells via mismatched MHC-I mole-
cules can happen. On the other hand, mechanisms of NK
allotolerance may also be involved in the differential
growth of these tumors in full vs partial chimeras. As dem-
onstrated in an elegant study on mosaic mice, which
express a transgenic MHC-I allele in only part of their cells
[57], NK cells develop dominant tolerance to cells lacking
MHC-I transgene expression. Interestingly however, this
form of induced NK allotolerance, which so far is poorly
understood at the molecular level, has been shown to be
dependent on the continuous presence of tolerizing cells
lacking the MHC-I transgene, but to be readily reversible
on removal of these cells. Thus, in a chimeric tissue, NK
cells would be expected to be dominantly tolerant of miss-
ing or mismatched MHC-I molecules, whereas in a non-
chimeric tissue NK alloreactivity should be restored on
migration of NK cells from chimeric to allogeneic tissues.
Based on this notion, NK alloreactivity to the same tumor
should be highly dependent on the level of chimerism of
the affected organ, which would be in perfect accordance
with our experimental findings. In addition, NK-mediated
tumor killing may not be operative in fully chimeric tis-
sues, due to the suppressive cytokine environment gener-
ated via peripheral CD8+ Treg cells [58-60] as discussed
above, allowing the tumor to escape also from innate
immunity.
Conclusion
While direct experimental evidence for most of these
assumptions is still lacking and will have to await further
studies, important conclusions can be drawn from the
data at hand.
First, our data suggest that tolerance to self structures in
chimeric mice may be maintained primarily by peripheral
tolerance mechanisms, potentially also resulting in a
reduced level of overall adaptive immunity, as exempli-
fied by the enhanced growth of B16 tumors in chimeric vs
syngeneic skin. Still however, these mice are healthy and
do not seem to suffer from an increase in spontaneous
infections. This suggests that such a reduced level may be
well compensated for by other mechanisms of immunity,
possibly provided by the innate immune system. Second,
and with special respect to tumor immunity, our data also
suggest that rejection of tumors by the host immune sys-
tem is primarily controlled by the local immune milieu of
the tumor site, irrespective of the level of systemic adap-
tive immunity to the very same structures. This comes as
quite a surprise and at the same time raises questions
about the concept of therapeutic tumor vaccinations. On
the other hand, the independence of tumor rejection
observed in the non-chimeric skin of otherwise chimeric
mice of established central tolerance, as demonstrated by
rapid tumor growth at other sites than the skin, suggests
that local tumor rejection may be mainly dependent on
innate mechanisms, possibly involving NK cells and mac-
rophages. Given this notion and the highly efficient rejec-
tion of the B16 tumors in the skin of partial chimeras as
compared to syngeneic hosts, one cannot help but won-
der whether the natural role of the adaptive immune sys-
tem during tumor progression is not predominantly a
tumor-protective rather than a defensive one, actually hin-
dering the execution of innate and adaptive antitumor
mechanisms alike. Future work will thus be devoted to
elucidating the relative roles of various components of the
immune system for the rejection of tumors in these
unique chimeras, as a model for local antitumor immune
reactions.
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